ProQR Announces Year End 2025 Operating and Financial Results ProQR (Nasdaq: PRQR) reported year-end 2025 results and a pipeline update. Key points: €92.4M cash at Dec 31, 2025, €52.8M net cash used in operations, €44.7M R&D spend, and a €42.2M net loss. Clinical progress includes AX-0810 Phase 1 dosing with target engagement data expected 1H 2026; Development Candidates selected for AX-2402 and AX-2911. The company achieved $4.5M in Eli Lilly collaboration milestones, supporting runway into mid-2027.

#PRQR ProQR Announces Year End 2025 Operating and Financial Results

www.stocktitan.net/news/PRQR/pro-qr-announc...

ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced

#PRQR ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

www.stocktitan.net/news/PRQR/pro-qr-announc...

Trade Alerts, Monday January 12, 2026 – Crystal Equity Research

Small-cap stocks with declining money flow, Mon Jan 12th - #TLS #STKL #SEPN #RBBN #PRQR #OM #NWL #NAGE #MDWD #IART #HNRG #GEMI #FCCO #EQ #DOMO #CLNN #BTBT #AUTL #SI #OPFI #JBI #CPF #CDRE #AHT - More: crystalequityresearch.com/trade-alerts... - #smallcap

#PRQR ProQR Announces Third Quarter 2025 Operating and Financial Results

www.stocktitan.net/news/PRQR/pro-qr-announc...

Breaking News: ( NASDAQ: #PRQR ) Expected earnings - ProQR Therapeutics N.V.

ProQR Announces Second Quarter 2025 Operating and Financial Results ProQR Therapeutics (Nasdaq: PRQR) reported its Q2 2025 financial and operational results, highlighting significant progress in its RNA editing pipeline. The company has submitted a Clinical Trial Application for AX-0810, its lead program targeting NTCP for cholestatic diseases, with initial Phase 1 data expected in Q4 2025.ProQR maintains a strong financial position with €119.8 million in cash, providing runway into mid-2027. The company reported a net loss of €22.3 million for H1 2025. Notable developments include advancing AX-2402 for Rett Syndrome and achieving $2.0 million in milestone payments from its Eli Lilly collaboration, with potential for additional milestone income and expansion options.

#PRQR ProQR Announces Second Quarter 2025 Operating and Financial Results

www.stocktitan.net/news/PRQR/pro-qr-announc...

Breakthrough: ProQR's Revolutionary RNA Editing Platform Enters First Human Clinical Trial for Liver Disease Treatment First-in-human trial of AX-0810 targets NTCP protein to combat liver diseases. See how this RNA editing breakthrough could transform treatment. Get trial timeline.

#PRQR ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

www.stocktitan.net/news/PRQR/pro-qr-announc...

ProQR Therapeutics #PRQR - large shareholder is angry that the board of directors is ignoring shareholder concerns - Van Herk is the shareholder and details are in the 13D. If you are a shareholder in a micro cap often the only way for you to get treated fairly is to run a proxy contest.

ProQR Announces First Quarter 2025 Operating and Financial Results ProQR Therapeutics (NASDAQ: PRQR) reported its Q1 2025 financial results and business updates. The company maintains a strong financial position with €132.4 million in cash, providing runway into mid-2027. ProQR's lead RNA editing program, AX-0810, targeting NTCP for cholestatic diseases, is on track for CTA filing in Q2 2025, with initial clinical data expected in Q4. The company strengthened its leadership by appointing Dennis Hom as CFO and Dr. Cristina Lopez Lopez as CMO. For Q1 2025, ProQR reported R&D costs of €12.3 million, general and administrative costs of €3.2 million, and a net loss of €10.1 million (€0.10 per share). The company earned a $1.0 million milestone payment from its Eli Lilly partnership, with potential for additional milestones and expansion to 15 targets that would trigger a $50 million opt-in payment.

#PRQR ProQR Announces First Quarter 2025 Operating and Financial Results

www.stocktitan.net/news/PRQR/pro-qr-announc...

RNA Editing Pioneer ProQR to Showcase Breakthrough Axiomer Platform at Major Healthcare Conference RNA therapeutics leader ProQR to discuss Axiomer platform innovations at Citizens conference. Join the live fireside chat May 8. Get exclusive insights.

#PRQR ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

www.stocktitan.net/news/PRQR/pro-qr-announc...

AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline — Airna Financing led by Venrock Healthcare Capital Partners with co-lead Forbion Growth, and participation from RTW Investments, Nextech Invest, and other new

#prqr $prqr #proqr

Ok $155m raised. Thats around mkt cap of ADAR patent owner ProQR. How cheap.

airna.com/news/airna-r...

ProQR Secures 3-Year Runway with €149M War Chest, 4 Clinical Readouts Coming RNA editing leader ProQR strengthens position with €149.4M cash reserve and pipeline advancement. Four clinical readouts expected 2025-2026, including key NTCP program.

#PRQR ProQR Announces Year End 2024 Operating and Financial Results

www.stocktitan.net/news/PRQR/pro-qr-announc...

ProQR Secures $8.1M Funding Boost to Advance Revolutionary Rett Syndrome Treatment ProQR expands collaboration with RSRT, securing $9.1M total funding to develop RNA-editing therapy for Rett syndrome, targeting 350,000 patients worldwide.

#PRQR ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration

#news #investing #stocks

www.stocktitan.net/news/PRQR/pro-qr-therape...

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #EQT 17.4x
2. #EOSE 16.0x
3. #CSCO 10.6x
4. #PRQR 9.5x
5. #SYF 7.3x

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #M 4.5x
2. #DNN 4.4x
3. #SVC 4.3x
4. #PRQR 4.2x
5. #PPC 4.2x

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #CLSK 58% OTM
2. #OKLO 37% OTM
3. #PRQR 36% OTM
4. #TSLA 30% OTM
5. #TGS 28% OTM

#OptionFlow #OptionsTrading #Trading

JUST IN: ( NASDAQ: #PRQR ) ProQR Announces Second Quarter 2024 Operating and Financial Results

#StockMarket #News